Abivax says new Phase 3 data show cancer rates within expected range for its UC drug obefazimod, though Jefferies flags lingering FDA risk.
Late on Monday, Abivax released new trial data on its ulcerative colitis candidate, showing that cancer cases in a Phase 3 trial were within the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered 'landmark' results, and the drug's safety…
French biotech company Abivax said new clinical trial data supports the safety and effectiveness of its experimental ulcerative…
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares…
Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent…
Abivax shares plunge more than 35% as cancer cases reported in a Phase 3 trial overshadow strong efficacy results for ulcerative…
Abivax's Phase 3 ulcerative colitis data met remission goals, but cancer cases in the study raised safety questions and analyst…
Abivax balza del 36%: i dati riducono i timori su obefazimod
